Subjects
Five independent studies were included in our study comprising a total of 3,053 unrelated Caucasian patients with clinically documented late stage AMD (cases) and 2,738 unrelated age and individuals with comparable age range and ethnicity without signs of macular disease (controls) (Table 1). All data were available for analysis at the analysis center in Regensburg. Discovery study GER1 (stage 1) included 710 AMD patients and 612 controls from the University Eye Clinic of Würzburg (Germany). The four replication studies (Stage 2) comprised (1) 996 AMD patients and 645 controls from the University Eye Clinics in München, Tübingen and Würzburg (Germany) (GER2); (2) 681 AMD patients and 367 controls from Columbia University (New York, USA) (US); (3) 300 AMD patients and 183 controls from the Royal Victoria Hospital (Belfast, UK) (UK); and (4) 542 AMD patients and 1,028 controls from the Department of Ophthalmology at the University Hospital Cologne, Germany (COL). Cases and controls were examined by trained ophthalmologists. Stereo fundus photographs were graded according to standardized classification systems as described previously (Grassmann et al. 2012). The study was conducted at all sites in strict adherence to the tenets of the Declaration of Helsinki and was approved by the respective Ethics Committees at the University Eye Clinics of Würzburg, München and Tübingen, by the Institutional Review Board at Columbia University, by the Research Ethics Committee of Queen’s University Belfast and by the local Ethics Committee in Cologne.
Genotyping
Genomic DNA was extracted from peripheral blood leukocytes according to established protocols. Genotyping of SNPs was carried out by direct sequencing, TaqMan SNP genotyping (Applied Biosystems, Foster City, USA) or by primer extension of multiplex PCR products and subsequent allele detection by matrix-assisted laser desorption/ionization time of flight (MALDI-TOF; Sequenom, San Diego, USA). Direct sequencing was performed with the Big Dye Terminator Cycle sequencing kit version 1.1 (Applied Biosystems, Foster City, U.S.A.) according to the manufacturer’s instructions. Reactions were analyzed with an ABI Prism 3130xl sequencer (Applied Biosystems). TaqMan pre-designed SNP genotyping assays (Applied Biosystems) were used according to the manufacturer’s instructions. The rs144087548 variant was genotyped by polymerase chain reaction (forward primer: 5′-CGC AGA CAT GAT GCT GGG GGT-3′; reverse primer: 5′-ACA TGC AAG ACG GGG AAT TGA-3′) followed by HpyCH4III digestion (New England Biolabs, Ipswich, USA) and restriction fragment length analysis. All SNPs showed high genotyping quality with an average call rate >98 % in each of the five case–control samples.
Statistical Methods
Discovery Study
We excluded three SNPs [rs2279227 (RGR), rs4620343 and rs3812532 (TRPM3)], each with significant deviation from Hardy–Weinberg equilibrium (HWE, P ≤ 0.05) in the control group of the discovery sample. SNP association analysis was carried out by logistic regression adjusted for age and sex. All analyses modeled an additive genetic effect and the genotype was coded as the number of alleles present at a given variant (i.e., 0, 1 or 2).
Replication Studies and Combined Analysis
All SNPs were in HWE (P > 0.05). We used the same tests for SNP association analysis as in the discovery study. We also combined the individual data from all five studies and also adjusted the respective analyses by study center (coded as factors). The I
2 measure was computed to measure between-study heterogeneity. We also conducted sex-stratified analyses for each study separately and for all study samples combined. Sex differences were asses for statistical significance using a t test derived from sex-specific beta estimates and corresponding standard errors.
All reported P values were two-sided except where noted otherwise. All SNP association analyses were carried out with R (v3.0.1, http://R-Forge.R-project.org/). To allow a more detailed inspection of the genomic region of interest, measures of LD were calculated using R package snp.plotter (Luna and Nicodemus 2007).
Imputation of SNPs
Prior to imputation, 8 tag SNPs in DAPL1 were phased in the GER1 study individuals using SHAPEIT2 (Delaneau et al. 2013). Then, untyped SNPs were imputed with IMPUTE2 (Howie et al. 2009) using the 1,000 Genomes Phase I integrated haplotypes (release 20110521) as reference panel. After the exclusion of SNPs with imputation quality (“info”) <0.5, the genotype probabilities (dosages) of the remaining SNPs were also analyzed by logistic regression in R, using an additive model adjusted for age and sex.
Genomic Resequencing
Genomic resequencing was done for regions of interest defined by the presence of certain gene elements (putative promoter, coding exons of transcripts NM_001017920.2, HQ179935, HQ179936, and HQ179937) or conserved elements based upon the “46-Way Most Cons” track of the UCSC genome browser, NCBI Build 37/hg19. Regions within extensive repeat structures were excluded (Supplementary Figure S3). Resequencing primers are listed in Supplementary Table S4.
Prediction of Functional Impact of Risk Variants
The functional impact AMD-associated SNPs (with known dbSNP ID) on RNA processing as well as protein sequence, structure and function was predicted using the web-based “SNP Function Prediction” tool implemented in the “SNPinfo Web Server” (http://snpinfo.niehs.nih.gov/index.html) (Xu and Taylor 2009). For newly identified SNPs, we used ESEfinder 3.0 to predict the effect of a given SNP allele on putative exonic splicing enhancers (
http://rulai.cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi) (Cartegni et al. 2003).
Characterization of Major Splice Variants of DAPL1 in Human Retina/RPE
To determine major splice variants and functional polyadenylation sites, 3′ rapid amplification of cDNA ends (3′-RACE) experiments were conducted. RNAs from RPE/retina tissues that were either heterozygous (ID_13 and ID_14) or homozygous (ID_16 and ID_17) for the non-risk rs17810398:C allele were isolated by RNeasy Mini Kit followed by DNAse I treatment (QIAGEN, Hilden, Germany). 3′-RACE was conducted with the FirstChoice RLM-RACE Kit (Applied Biosystems/Ambion, Austin, USA) according to the manufacturer’s instructions. Forward primers for first and second (nested) PCR were 5′-GCA CTG GCA CACG CTA TG-3′ and 5′-TTG GCA CCT TGG AAA GAC ATA CC-3′, respectively. Amplified RACE products were ligated into the pGEM-T vector (Promega, Madison, USA). PCR products were obtained with M13 forward and M13 reverse primers from a total of 1,200 clones. Of these, 597 clones were sequenced; the remaining 603 could unequivocally be assigned to DAPL1 isoform 1 (NM_001017920.2, HQ179934) by visual gel inspection. The sequences of isoforms 2–6 were submitted to GenBank (HQ179935, HQ179936, HQ179937, HQ179938, HQ179939).
Expression Analysis and Semi-quantitative Resequencing
Eight RPE/retina tissues with risk variant genotypes as given in Fig. 3 and Supplementary Table S6 were used as templates to amplify isoform-specific PCR products with forward primer 5′-GCA CTG GCA CAC GCT ATG-3′ and the isoform-specific reverse primers 5′-CGA GGC TGC TGA ATA ATG TAG-3′ (isoform 1 & 2), 5′-TCT GGA TCC TCT GAG CTT CTT CTC-3′ (isoform 3) or 5′-CTG GAT CCT CTG AGC TTC TTG TGT-3′ (isoform 4), followed by sequencing with the forward primer. Primers for the GUSB gene were 5′-ACT ATC GCC ATC AAC AAC ACA CTC ACC-3′ and 5′-GTG ACG GTG ATG TCA TCG AT-3′. For tissue samples, sex was determined with fluorescence-based PCR analysis of the homologous, X- and Y-linked genes AMELX and AMELY as described in Sullivan et al. (1993).